Bausch Health Cos Inc. $BHC Shares Purchased by Chicago Partners Investment Group LLC

Chicago Partners Investment Group LLC boosted its holdings in Bausch Health Cos Inc. (NYSE:BHC) by 6,366.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 757,203 shares of the company’s stock after acquiring an additional 745,493 shares during the quarter. Chicago Partners Investment Group LLC’s holdings in Bausch Health Cos were worth $4,876,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Paulson & CO. Inc. bought a new stake in shares of Bausch Health Cos in the 2nd quarter worth approximately $361,151,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Bausch Health Cos during the 2nd quarter valued at $1,167,000. Dimensional Fund Advisors LP boosted its stake in shares of Bausch Health Cos by 10.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,604,818 shares of the company’s stock worth $19,456,000 after acquiring an additional 350,823 shares in the last quarter. MFN Partners Management LP acquired a new stake in shares of Bausch Health Cos in the second quarter worth about $29,580,000. Finally, Bank of America Corp DE bought a new stake in shares of Bausch Health Cos during the 2nd quarter worth about $2,816,000. 78.65% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Bausch Health Cos

In other news, insider Aimee Lenar sold 36,827 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $7.03, for a total value of $258,893.81. Following the completion of the sale, the insider owned 334,853 shares of the company’s stock, valued at approximately $2,354,016.59. The trade was a 9.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 20.67% of the company’s stock.

Bausch Health Cos Price Performance

Shares of Bausch Health Cos stock opened at $7.99 on Friday. The firm has a market cap of $2.99 billion, a price-to-earnings ratio of -3.49 and a beta of 0.30. The stock’s 50-day moving average is $6.36 and its 200-day moving average is $5.74. Bausch Health Cos Inc. has a one year low of $4.33 and a one year high of $9.04.

Bausch Health Cos (NYSE:BHC) last released its quarterly earnings results on Wednesday, October 28th. The company reported $1.77 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.52. The business had revenue of $2.90 billion during the quarter, compared to analysts’ expectations of $2.72 billion. Bausch Health Cos had a negative return on equity of 401.73% and a negative net margin of 7.57%. On average, equities analysts expect that Bausch Health Cos Inc. will post 4.35 EPS for the current year.

Analyst Ratings Changes

BHC has been the topic of a number of recent analyst reports. Wall Street Zen raised Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Jefferies Financial Group lifted their price target on shares of Bausch Health Cos from $6.50 to $8.00 and gave the company a “hold” rating in a research report on Thursday, October 29th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Bausch Health Cos in a report on Thursday, October 29th. Zacks Research upgraded shares of Bausch Health Cos from a “hold” rating to a “strong-buy” rating in a report on Monday, September 21st. Finally, Royal Bank Of Canada boosted their target price on shares of Bausch Health Cos from $9.00 to $10.00 and gave the stock a “sector perform” rating in a research report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Bausch Health Cos currently has an average rating of “Hold” and a consensus price target of $8.25.

Bausch Health Cos Company Profile

Bausch Health Companies Inc (NYSE:BHC) is a multinational specialty pharmaceutical company focused on developing, manufacturing and commercializing branded, generic and over-the-counter medicines. Its portfolio serves several therapeutic areas, including gastroenterology, dermatology, neurology, ophthalmology, hospital products and other specialty-care markets.

The company markets products through businesses such as Salix Pharmaceuticals, Ortho Dermatologics, Solta Medical and its international pharmaceutical operations.